Table 1 Baseline characteristics at enrollment in the open-label extension phase, after 24 months of treatment with etanercept (baseline CLIPPER2)

% of CLIPPER

92% (55/60)

82% (31/38)

79% (23/29)

86% (109/127)

Age, years^a

10.6 (4.6)

16.2 (1.6)

15.8 (2.4)

13.3 (4.5)

Female^a

38 (69)

5 (16)

18 (78)

61 (56)

 Physician Global Assessment of disease activity, 0–100 score

1.0 (1.4)

n = 49

0.7 (0.7)

n = 30

0.8 (1.0)

n = 19

0.8 (1.2)

n = 98

 Number of active joints^a

0.6 (1.0)

n = 40

0.7 (1.2)

n = 28

1.3 (4.6)

n = 19

0.8 (2.3)

n = 87

 Number of joints with LOM^a

0.8 (1.1)

n = 40

1.4 (3.2)

n = 28

1.7 (5.0)

n = 19

1.2 (3.0)

n = 87

 C-reactive protein, mg/L^a

 (normal < 5 mg/L)

3.9 (8.5)

n = 47

2.7 (4.1)

n = 27

1.1 (0.2)

n = 18

3.0 (6.5)

n = 92

 PtGA score^a

1.4 (2.0)

1.0 (1.3)

1.3 (1.5)

1.3 (1.7)

 CHAQ score^a

0.3 (0.6)

n = 47

0.1 (0.2)

n = 20

0.2 (0.3)

n = 13

0.2 (0.5)

n = 80

 JADAS 73 score^a

3.5 (4.7)

n = 37

2.3 (2.2)

n = 25

3.3 (5.4)

n = 18

3.1 (4.3)

n = 80

 Overall back pain VAS, mm^a

–

n = 0

2.3 (4.8)

n = 26

–

n = 0

2.3 (4.8)

n = 26

 Nocturnal back pain VAS, mm^a

–

n = 0

2.1 (3.7)

n = 26

–

n = 0

2.1 (3.7)

n = 26

 Psoriasis BSA, percentage^a

–

n = 0

–

n = 0

1.4 (2.4)

n = 19

1.4 (2.4)

n = 19

 PGA of psoriasis^a

–

n = 0

–

n = 0

0.6 (0.9)

n = 19

0.6 (0.9)

n = 19

 Any DMARD

50 (91)

28 (90)

19 (83)

97 (89)

 Methotrexate

45 (82)

17 (55)

16 (70)

78 (72)

 Oral corticosteroid

7 (13)

7 (23)

1 (4)

15 (14)

 Oral NSAID

26 (47)

19 (61)

9 (39)

54 (50)